Want to see ELDN full AI Analyst Report?
ELDN Stock Chart & Stats
$3.32
-$0.02(-0.56%)
At close: 4:00 PM EDT
$3.32
-$0.02(-0.56%)
Day’s Range― - ―
52-Week Range$1.35 - $4.60
Previous CloseN/A
Volume630.04K
Average Volume (3M)824.51K
Market Cap
$183.24M
Enterprise Value$398.44M
Total Cash (Recent Filing)$88.76M
Total Debt (Recent Filing)$467.00K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 18, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume807,577
30 Day Avg. Volume824,511
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
$8.67Price Target Upside161.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency pressure and interest obligations while preserving flexibility to fund clinical development. Although the company remains loss-making, its capital structure is not currently burdened by significant borrowing, which may provide greater strategic options than a highly leveraged biotechnology peer.
Targeted Immunology PlatformTegoprubart is designed around a targeted immune-modulation mechanism rather than broad immunosuppression, giving Eledon a differentiated scientific focus. If clinical development succeeds, this approach could support more effective transplantation outcomes and create a foundation for additional immunology applications.
Multiple Disease ApplicationsEledon’s lead program addresses more than one disease area, including transplantation and autoimmune conditions. This broadens the potential commercial application of successful development and could create multiple paths for future product expansion, although those opportunities remain dependent on clinical and regulatory success.
Bears Say
No Operating RevenueThe absence of operating revenue means Eledon currently depends on external capital rather than product sales to support its business. Until a candidate is approved and commercialized, the company has no established revenue engine to offset research spending or provide internally generated funding for continued development.
Deepening LossesLarge and recently worsening losses show that Eledon remains far from breakeven and that operating expenses are not yet supported by revenue. Persistent negative EBIT reduces financial resilience and increases the amount of capital required before the company can become self-sustaining through commercial operations.
Persistent Cash BurnContinued negative operating and free cash flow indicates that clinical operations consume substantial cash without producing funding internally. The recent deterioration increases the likelihood that Eledon will need additional financing to maintain development, creating potential dilution and reducing flexibility if capital markets become less supportive.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.60 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $183.24M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Aug 13, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.112.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 81,261,154 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -4.324%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (161.04% Upside)
$8.67 (161.04% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 70.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.24%
12-Months-Change
Fundamentals
Return on Equity
-136.45%
Trailing 12-Months
Asset Growth
-12.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$8.67
▲(161.04% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
7.63% Mutual Funds
0.30% Other Institutional Investors
82.03% Public Companies and
Individual Investors